Objective: Angiogenesis is one of the crucial steps in various solid tumor growth and metastasis. However, there are limited data regarding the clinical and prognostic significance of serum vascular endothelial growth factor levels per platelet count in unresectable advanced gastric cancer compared with early gastric cancer and healthy volunteers. Methods: A total of 181 gastric cancer patients were included and control serum samples were acquired from 113 healthy volunteers. The levels of serum vascular endothelial growth factor were measured using human vascular endothelial growth factor quantitative enzymelinked immunosorbent assay. Survival curves were calculated using the Kaplan -Meier method and survival comparisons were made by the log-rank test in metastatic gastric cancer.
INTRODUCTION
Vascular endothelial growth factor (VEGF) is a dimeric, heparin-binding glycoprotein that can be expressed in four isoforms, which have 206, 189, 165 and 121 amino acids, respectively (1) . VEGF induces endothelial cell growth and functions as a potent mitogen of vascular endothelial cells, providing an opportunity for their migration and the neovascularization of micrometastases (2) . Activation of the VEGF/ VEGF-receptor (VEGFR) axis triggers multiple signaling pathways that result in endothelial cell survival, mitogenesis, migration, and differentiation, and vascular permeability. From 1995, a number of studies have shown that high tissue VEGF levels correlate with prognosis of patients with breast cancer, colorectal carcinoma, prostate cancer, lung cancer, pancreatic cancer, melanoma and gastric cancer (3 -9) . Recent studies have shown that VEGF expression not in tissues but in serum sample is correlated with tumor vascularity, and high serum VEGF levels could predict poor prognosis in cancer patients (10, 11) . However, VEGF is stored in alpha granule and is released on platelet activation during clotting and peripheral blood cells such as platelets, granulocyte, lymphocytes also express VEGF (12) , serum VEGF may be an inaccurate indicator of tissue VEGF. Thus, a couple of recent studies used VEGF per platelet count to correct variation of serum VEGF levels in cancer patients with different platelet counts (13, 14) .
Gastric cancers in locally advanced or metastatic stages are the second leading cause of cancer death in Korea (15) , and the overall response rate of chemotherapy in advanced gastric cancer is 30 -50% (16) . Gastric cancer cells produce a variety of growth factors such as VEGF, interleukin-8, basic fibroblast growth factor and platelet-derived endothelial growth factor (8, 17, 18) . The prognosis in patients with tumors displaying high VEGF expression levels was significantly poorer than those with low expression levels (10). Serum VEGF-A or C levels were significantly correlated with response to surgical treatment and recurrence in gastric cancer patients (11, 19, 20) . Moreover, there has been a recent study showing that high preoperative serum VEGF levels predict poor clinical outcome after curative resection of gastric cancer (21) . But the study regarding the clinical significance of serum VEGF levels in unresectable advanced gastric cancer patients has not been findable. So, we conducted this study to evaluate the prognostic implication of serum VEGF level itself and the level corrected by platelet count in advanced gastric cancer patients. Peripheral venous blood samples were collected into plain serum tubes at the time of diagnosis or before the start of treatment for gastric cancer. Within 1 h of collection, the samples were centrifuged at 3000 rpm for 10 min, then stored at 2708C. Serum VEGF levels were measured using a commercially available human VEGF quantitative enzymelinked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA), with the standard solutions supplied, in accordance with the manufacturer's instructions. All analyses were performed in duplicate and the mean values were used for statistical calculations.
PATIENTS AND METHODS

PATIENTS
STATISTICAL ANALYSIS
The Kruskal -Wallis test, the Mann -Whitney U-test and the Wilcoxon rank test were used to evaluate differences between subgroups, unpaired and paired observations, respectively. Correlation between serum VEGF and platelet counts was evaluated using the Spearman's rank test. Overall survival was calculated from beginning of treatment in the study until death. Progression-free survival was calculated from the first day of the chemotherapy until the date of progression or the date of last follow-up for any other reasons. Survival curves were calculated using the Kaplan -Meier method and survival comparisons were made using the log-rank test in metastatic gastric cancer. The Cox proportional hazards regression model was utilized for multivariate analyses after univariate analysis defined relevant prognostic variables in advanced gastric cancer. All data are expressed as mean + standard error of the mean. A two-sided P-value ,0.05 was considered statistically significant. The software package SPSS (version 12.0.0, SPSS Inc., Chicago, IL, USA) was used for the statistical calculations. Table 1 shows the baseline characteristics of the patients with advanced gastric cancer. Of these patients, 130 patients (87.8%) had an ECOG performance status of 0 or 1 and 98 patients (66.2%) had stage IV gastric cancer. Of the 148 patients with AGC, 88 (59.4%) patients were treated with chemotherapy and 79 out of 88 patients were assessable for response. Median serum VEGF was 446.0 (30.5 -1784.0) pg/ml and median platelet count (X 106 /ml) was 240 (68 -695). The mean
RESULTS
CHARACTERISTICS OF THE PATIENTS AND CONTROLS
1148
Serum VEGF per platelet in advanced gastric cancer serum VEGF level was higher in the patients with AGC compared with those with EGC and controls (AGC: 543.6 + 375.7 pg/ml; EGC: 498.1 + 336.5 pg/ml controls 319.8 + 137.5 pg/ml, P ¼ 0.000, Fig. 1 ).
CORRELATION BETWEEN SERUM LEVELS OF VEGF AND PLATELET COUNTS
A trend towards a significant positive correlation between serum VEGF and platelet counts was observed in patients with AGC (r ¼ 0.364, P ¼ 0.0002, Fig. 2 ). We assessed the relationship between serum VEGF levels, serum VEGF per platelet and the clinical and pathological features of the disease. Serum VEGF levels showed a significant correlation with tumor differentiation (P ¼ 0.014) and with stage (P ¼ 0.036). Although serum VEGF and serum VEGF per platelet count did not show correlation with peritoneal carcinomatosis, response to chemotherapy, or distant metastasis, we observed a correlation between serum VEGF per platelet count and tumor differentiation (P ¼ 0.027) ( Table 2 ).
THE RELATIONSHIP OF SERUM VEGF PER PLATELET COUNT TO SURVIVAL
Of the 148 patients with advanced gastric cancer, 128 patients were alive and 20 patients had died at the end of follow-up.
The causes of death included disease progression (n ¼ 15), sepsis (n ¼ 4), and microangiopathic hemolytic anemia (n ¼ 1). The median progression-free survival (PFS) was 9.1 months (range: 0.3-14.3 months); the overall median survival was not reached (range: 0.3 -17.6 months). We analyzed the relationship of serum VEGF per platelet count with overall survival and progression-free survival in patients with metastatic gastric cancer. The group with high-serum VEGF per platelet count (1.626 pg/10 6 ) and that with low-serum VEGF per platelet count (,1.626 pg/10 6 ) were divided by the median value. The overall survival was shorter in patients with high VEGF per platelet count (log rank, P ¼ 0.0432) (Fig. 3a) . The progression-free survival was also significantly shorter in patients with high-serum VEGF per platelet count (median 4.5 vs. 8.9 months; log rank, P ¼ 0.0116) (Fig. 3b) . 
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The value of prognostic variables was determined by Cox proportional hazard regression analysis in advanced gastric cancer patients (N ¼ 181). Prognostic variables evaluated by univariate analysis included age, gender, performance status, tumor differentiation, TNM stage, the presence or absence of peritoneal carcinomatosis and serum VEGF per platelet count. In the univariate analyses, performance status, TNM stage and serum VEGF per platelet count were related to poor overall survival (P ¼ 0.001, P ¼ 0.048 and P ¼ 0.042, respectively, Table 3 ). The multivariate regression analysis, however, did not confirm this relationship for either VEGF per platelet count (hazard ratio: 1.39; 95% CI: 0.99 -1.95; P ¼ 0.057) or TNM stage (hazard ratio: 2.15; 95% CI: 0.78 -5.89; P ¼ 0.137). Performance status was related to poor overall survival (hazard ratio: 3.27; 95% CI: 1.10 -9.76; P ¼ 0.033).
Further analyses of these same variables, with respect to progression-free survival, were performed using a Cox regression model. Univariate analysis showed that performance status (P ¼ 0.001), TNM stage (P ¼ 0.0002), the presence of peritoneal carcinomatosis (P ¼ 0.0004), serum VEGF levels (P ¼ 0.038) and serum VEGF per platelet count (P ¼ 0.005) significantly influence progression-free survival ( Table 4 ). The multivariate analysis confirmed the significant negative effect of the presence of peritoneal carcinomatosis (hazard ratio: 1.97; 95% CI: 1.04 -3.74; P ¼ 0.039) and serum VEGF per platelet (hazard ratio: 1.82; 95% CI: 1.19 -2.76; P ¼ 0.005) on progression-free survival (Table 5) .
DISCUSSION
The biological implications of VEGF in platelets for tumor's growth are not fully established yet. Platelets could adhere, aggregate and release locally their angiogenic contents in tumors. Advanced cancer patients have a higher platelet VEGF load and could therefore provide an additional stimulus to ongoing angiogenesis in tumors.
The most VEGF in the serum is released from platelets during clotting, elevated serum VEGF may be the consequence of increased platelet numbers in cancer patients caused by intratumoral platelet activation and subsequent release of thrombopoietin. Verheul et al. (22) , serum VEGF concentrations in breast cancer patients were determined by platelet counts and not by tumor burden, suggested that plasma VEGF instead of serum VEGF concentrations should be studied as a marker for tumor progression. But, considering the several reports showing the possible role of platelet for tumor seeding and metastasis (23, 24) , serum VEGF levels seems to have a sufficient significance. The debate is still under investigation, whether serum VEGF or plasma VEGF should be used as a marker of tumor progression or prognosis. Some studies show that platelet-poor plasma reflects more accurate tumor progression (25) , whereas others found that serum VEGF gives a better prognostic marker of tumor progression (26) . Therefore, Verheul and Pinedo (23) strongly recommend in any study regarding circulating VEGF to include plasma and serum levels, and platelet counts, further studies are required to define the Jpn J Clin Oncol 2010;40(12) 1151 optimal sample processing for the analysis of circulating VEGF levels. The serum assay for VEGF using ELISA can be frequently and easily performed because it is non-invasive method in obtaining serum samples in contrast to surgically obtained tissue materials, which might make it useful in monitoring the course of disease or response to treatment. To correct for variation in platelet counts between patients, some studies were reported using serum VEGF, plasma VEGF and platelet count. George et al. (14) measured these levels and calculated that 'plasma-corrected VEGF/platelet' (serum-plasma VEGF/platelet [in pg/ml]) and serum VEGF per platelet in colorectal cancer. They concluded that plasma VEGF levels are low and lie close to the limits of currently available ELISA assay, so serum VEGF per platelet are more informative with regard to prognosis. Majority of the study regarding VEGF in cancer patients were tried to predict the surgical outcome (11,27 -31) . As a study for cancer patients medically treated, Kim et al. (13) reported that patients with high-serum VEGF per platelet count showed poor response to treatment and shorter overall survival, serum VEGF per platelet count was an independent prognostic factor with the presence of portal vein thrombosis in patients with hepatocellular carcinoma. Hepatocelluar carcinoma is a hypervascular cancer. So, the generalization of the result of Kim et al. to all of the cancer patients medically treated might be difficult. So, we tried this study and can identify the significance of serum VEGF per platelet count to the medically treated cancer patients without hypervascularity.
There are some weak points in this study. This study was tried retrospectively. So, the sample size seems to be relatively small. And a large proportion of patients had unresectable advanced stage (IV) with poor prognosis, and most patients were enrolled in our study at the time were in the status of chemotherapy or after chemotherapy. In spite of these limitations, our study results might be a firstly strengthen the significance of serum VEGF per platelet count to predict the prognosis of advancer gastric cancer patients medically treated. Therefore, additional prospective studies must be performed to confirm its role as a useful surrogate marker of gastric cancer progression.
